• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

20.08 +0.98 (+5.13%)
Streaming Delayed Price Updated: 2:47 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 839,665
Open 18.96
Bid (Size) 20.08 (400)
Ask (Size) 20.13 (100)
Prev. Close 19.10
Today's Range 18.70 - 20.60
52wk Range 3.420 - 30.00
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
March 23, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool

Performance

YTD
-11.6%
-11.6%
1 Month
+0.9%
+0.9%
3 Month
-13.2%
-13.2%
6 Month
+15.9%
+15.9%
1 Year
+107.9%
+107.9%

More News

Read More
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
March 18, 2026
Via The Motley Fool
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗
March 02, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q4 2025 Earnings Call Transcript ↗
March 02, 2026
Via The Motley Fool
Topics Earnings
News headline image
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
March 02, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
February 27, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
February 23, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
February 04, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
January 05, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
December 26, 2025
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q3 2025 Earnings Call Transcript ↗
November 06, 2025
Via The Motley Fool
Topics Earnings
News headline image
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗
November 06, 2025
Via Chartmill
News headline image
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
November 06, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
November 06, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 20.08
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 04/09/26 02:47 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 725.49M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 725M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap